Executive Director, Analytical Sciences

Location: Princeton, NJ (on-site)

About Summit:

Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs. At Summit, we believe in building a team of world class professionals who are passionate about this mission, and it is our people who drive this mission to reality. Summit’s core values include integrity, passion for excellence, purposeful urgency, collaboration, and our commitment to people. Our employees are truly the heart and soul of our culture, and they are invaluable in shaping our journey toward excellence.

Summit’s team is inspired to touch and help change lives through Summit’s clinical studies in the field of oncology. Summit has multiple global Phase 3 clinical studies, including:

Non-small Cell Lung Cancer (NSCLC)

• HARMONi: Phase 3 clinical study which was intended to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a 3rd generation EGFR TKI.
• HARMONi-3: Phase 3 clinical study which is intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC.
• HARMONi-7: Phase 3 clinical study which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC.

Colorectal Cancer (CRC)

• HARMONi-GI3: Phase 3 clinical study intended to evaluate ivonescimab in combination with chemotherapy compared with bevacizumab plus chemotherapy.

Ivonescimab is an investigational therapy not presently approved by any regulatory authority other than China’s National Medical Products Administration (NMPA). Summit is headquartered in Miami, Florida, and has additional offices in California, New Jersey, the UK, and Ireland.

Overview of Role:

The Executive Director, Analytical Sciences will provide strategic and operational leadership for all analytical activities supporting the development, registration, and commercialization of the Company’s lead bispecific antibody product. With the first Biologics License Application (BLA) already submitted, this role is critical to ensuring regulatory compliance, product control, and lifecycle readiness as the organization transitions from late-stage development into commercial supply.

The successful candidate will be accountable for the end-to-end analytical control strategy, including method development, qualification, transfer, and oversight of GMP release and stability testing executed through a virtual network of CDMOs and partner laboratories. This individual will act as a key CMC leader and regulatory partner, interfacing closely with Quality, Manufacturing, Regulatory Affairs, and external collaborators.

Role and Responsibilities:

Analytical Strategy & Product Control

• Own and continuously evolve the global analytical control strategy for clinical and commercial drug substance and drug product.
• Ensure analytical readiness to support BLA review, responses to regulatory questions, inspections, and post-approval commitments.
• Define analytical lifecycle management strategies aligned with ICH Q2/Q6/Q12 and global regulatory expectations.

Method Development, Qualification & Transfer

• Provide oversight and scientific leadership for:
• Method development and optimization
• Method qualification and validation
• Method transfer to internal and external laboratories
• Ensure analytical methods are phase-appropriate, robust, stability-indicating, and fit for commercial use.
• Troubleshoot complex analytical issues related to bispecific antibodies (e.g., he